世界の腫瘍治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Drugs for Oncology Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2001 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、腫瘍治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、標的療法、免疫療法（生物学的療法）、内分泌療法、その他）、用途別市場規模（血液がん、乳がん、胃腸がん、前立腺がん、呼吸器・肺がん、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・腫瘍治療薬の市場動向 ・企業の競争状況、市場シェア ・腫瘍治療薬の種類別市場規模（化学療法、標的療法、免疫療法（生物学的療法）、内分泌療法、その他） ・腫瘍治療薬の用途別市場規模（血液がん、乳がん、胃腸がん、前立腺がん、呼吸器・肺がん、その他） ・腫瘍治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Roche、Celgene、Novartis、Bristol-Myers Squibb、Johnson & Johnson、Merck & Co.、AstraZeneca、Pfizer、Amgen、Eli Lilly、AbbVie、Takeda、Astellas、Ipsen、Sanofi、Bayer、Biogen Idec、Teva、Otsuka、Eisai、Merck KGaA、Gilead Sciences） ・結論

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

Market Analysis and Insights: Global Drugs for Oncology Market
The global Drugs for Oncology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Oncology market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Oncology market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Oncology market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Oncology market.

Global Drugs for Oncology Scope and Market Size
Drugs for Oncology market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Drugs for Oncology Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Drugs for Oncology Market Perspective (2016-2027)
2.2 Drugs for Oncology Growth Trends by Regions
2.2.1 Drugs for Oncology Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Drugs for Oncology Historic Market Share by Regions (2016-2021)
2.2.3 Drugs for Oncology Forecasted Market Size by Regions (2022-2027)
2.3 Drugs for Oncology Industry Dynamic
2.3.1 Drugs for Oncology Market Trends
2.3.2 Drugs for Oncology Market Drivers
2.3.3 Drugs for Oncology Market Challenges
2.3.4 Drugs for Oncology Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Drugs for Oncology Players by Revenue
3.1.1 Global Top Drugs for Oncology Players by Revenue (2016-2021)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2016-2021)
3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs for Oncology Revenue
3.4 Global Drugs for Oncology Market Concentration Ratio
3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2020
3.5 Drugs for Oncology Key Players Head office and Area Served
3.6 Key Players Drugs for Oncology Product Solution and Service
3.7 Date of Enter into Drugs for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Drugs for Oncology Breakdown Data by Type
4.1 Global Drugs for Oncology Historic Market Size by Type (2016-2021)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2022-2027)

5 Drugs for Oncology Breakdown Data by Application
5.1 Global Drugs for Oncology Historic Market Size by Application (2016-2021)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Drugs for Oncology Market Size (2016-2027)
6.2 North America Drugs for Oncology Market Size by Type
6.2.1 North America Drugs for Oncology Market Size by Type (2016-2021)
6.2.2 North America Drugs for Oncology Market Size by Type (2022-2027)
6.2.3 North America Drugs for Oncology Market Size by Type (2016-2027)
6.3 North America Drugs for Oncology Market Size by Application
6.3.1 North America Drugs for Oncology Market Size by Application (2016-2021)
6.3.2 North America Drugs for Oncology Market Size by Application (2022-2027)
6.3.3 North America Drugs for Oncology Market Size by Application (2016-2027)
6.4 North America Drugs for Oncology Market Size by Country
6.4.1 North America Drugs for Oncology Market Size by Country (2016-2021)
6.4.2 North America Drugs for Oncology Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Drugs for Oncology Market Size (2016-2027)
7.2 Europe Drugs for Oncology Market Size by Type
7.2.1 Europe Drugs for Oncology Market Size by Type (2016-2021)
7.2.2 Europe Drugs for Oncology Market Size by Type (2022-2027)
7.2.3 Europe Drugs for Oncology Market Size by Type (2016-2027)
7.3 Europe Drugs for Oncology Market Size by Application
7.3.1 Europe Drugs for Oncology Market Size by Application (2016-2021)
7.3.2 Europe Drugs for Oncology Market Size by Application (2022-2027)
7.3.3 Europe Drugs for Oncology Market Size by Application (2016-2027)
7.4 Europe Drugs for Oncology Market Size by Country
7.4.1 Europe Drugs for Oncology Market Size by Country (2016-2021)
7.4.2 Europe Drugs for Oncology Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Drugs for Oncology Market Size (2016-2027)
8.2 Asia-Pacific Drugs for Oncology Market Size by Type
8.2.1 Asia-Pacific Drugs for Oncology Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Drugs for Oncology Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Drugs for Oncology Market Size by Type (2016-2027)
8.3 Asia-Pacific Drugs for Oncology Market Size by Application
8.3.1 Asia-Pacific Drugs for Oncology Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Drugs for Oncology Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Drugs for Oncology Market Size by Application (2016-2027)
8.4 Asia-Pacific Drugs for Oncology Market Size by Region
8.4.1 Asia-Pacific Drugs for Oncology Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Drugs for Oncology Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Drugs for Oncology Market Size (2016-2027)
9.2 Latin America Drugs for Oncology Market Size by Type
9.2.1 Latin America Drugs for Oncology Market Size by Type (2016-2021)
9.2.2 Latin America Drugs for Oncology Market Size by Type (2022-2027)
9.2.3 Latin America Drugs for Oncology Market Size by Type (2016-2027)
9.3 Latin America Drugs for Oncology Market Size by Application
9.3.1 Latin America Drugs for Oncology Market Size by Application (2016-2021)
9.3.2 Latin America Drugs for Oncology Market Size by Application (2022-2027)
9.3.3 Latin America Drugs for Oncology Market Size by Application (2016-2027)
9.4 Latin America Drugs for Oncology Market Size by Country
9.4.1 Latin America Drugs for Oncology Market Size by Country (2016-2021)
9.4.2 Latin America Drugs for Oncology Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Drugs for Oncology Market Size (2016-2027)
10.2 Middle East & Africa Drugs for Oncology Market Size by Type
10.2.1 Middle East & Africa Drugs for Oncology Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Drugs for Oncology Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Drugs for Oncology Market Size by Type (2016-2027)
10.3 Middle East & Africa Drugs for Oncology Market Size by Application
10.3.1 Middle East & Africa Drugs for Oncology Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Drugs for Oncology Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Drugs for Oncology Market Size by Application (2016-2027)
10.4 Middle East & Africa Drugs for Oncology Market Size by Country
10.4.1 Middle East & Africa Drugs for Oncology Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Drugs for Oncology Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Drugs for Oncology Introduction
11.1.4 Roche Revenue in Drugs for Oncology Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Details
11.2.2 Celgene Business Overview
11.2.3 Celgene Drugs for Oncology Introduction
11.2.4 Celgene Revenue in Drugs for Oncology Business (2016-2021)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Drugs for Oncology Introduction
11.3.4 Novartis Revenue in Drugs for Oncology Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Drugs for Oncology Introduction
11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2016-2021)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Drugs for Oncology Introduction
11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2016-2021)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drugs for Oncology Introduction
11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2016-2021)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Drugs for Oncology Introduction
11.8.4 Pfizer Revenue in Drugs for Oncology Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Drugs for Oncology Introduction
11.9.4 Amgen Revenue in Drugs for Oncology Business (2016-2021)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Drugs for Oncology Introduction
11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2016-2021)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Drugs for Oncology Introduction
11.11.4 AbbVie Revenue in Drugs for Oncology Business (2016-2021)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Drugs for Oncology Introduction
11.12.4 Takeda Revenue in Drugs for Oncology Business (2016-2021)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Details
11.13.2 Astellas Business Overview
11.13.3 Astellas Drugs for Oncology Introduction
11.13.4 Astellas Revenue in Drugs for Oncology Business (2016-2021)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Details
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Drugs for Oncology Introduction
11.14.4 Ipsen Revenue in Drugs for Oncology Business (2016-2021)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Details
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Drugs for Oncology Introduction
11.15.4 Sanofi Revenue in Drugs for Oncology Business (2016-2021)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Details
11.16.2 Bayer Business Overview
11.16.3 Bayer Drugs for Oncology Introduction
11.16.4 Bayer Revenue in Drugs for Oncology Business (2016-2021)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Details
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Drugs for Oncology Introduction
11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2016-2021)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Details
11.18.2 Teva Business Overview
11.18.3 Teva Drugs for Oncology Introduction
11.18.4 Teva Revenue in Drugs for Oncology Business (2016-2021)
11.18.5 Teva Recent Development
11.18 Otsuka
.1 Otsuka Company Details
.2 Otsuka Business Overview
.3 Otsuka Drugs for Oncology Introduction
.4 Otsuka Revenue in Drugs for Oncology Business (2016-2021)
.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Details
11.20.2 Eisai Business Overview
11.20.3 Eisai Drugs for Oncology Introduction
11.20.4 Eisai Revenue in Drugs for Oncology Business (2016-2021)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Details
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Drugs for Oncology Introduction
11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2016-2021)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Details
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Drugs for Oncology Introduction
11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2016-2021)
11.22.5 Gilead Sciences Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy (Biologic Therapy)
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Others
Table 7. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Drugs for Oncology Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Drugs for Oncology Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Drugs for Oncology Market Share by Regions (2016-2021)
Table 11. Global Drugs for Oncology Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Drugs for Oncology Market Share by Regions (2022-2027)
Table 13. Drugs for Oncology Market Trends
Table 14. Drugs for Oncology Market Drivers
Table 15. Drugs for Oncology Market Challenges
Table 16. Drugs for Oncology Market Restraints
Table 17. Global Drugs for Oncology Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Drugs for Oncology Market Share by Players (2016-2021)
Table 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2020)
Table 20. Ranking of Global Top Drugs for Oncology Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Drugs for Oncology Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Oncology Product Solution and Service
Table 24. Date of Enter into Drugs for Oncology Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Drugs for Oncology Revenue Market Share by Type (2016-2021)
Table 28. Global Drugs for Oncology Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Drugs for Oncology Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Drugs for Oncology Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Drugs for Oncology Revenue Market Share by Application (2016-2021)
Table 32. Global Drugs for Oncology Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Drugs for Oncology Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Drugs for Oncology Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Drugs for Oncology Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Drugs for Oncology Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Drugs for Oncology Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Drugs for Oncology Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Drugs for Oncology Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Drugs for Oncology Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Drugs for Oncology Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Drugs for Oncology Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Drugs for Oncology Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Drugs for Oncology Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Drugs for Oncology Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Drugs for Oncology Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Drugs for Oncology Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Drugs for Oncology Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Drugs for Oncology Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Drugs for Oncology Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Drugs for Oncology Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Drugs for Oncology Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Drugs for Oncology Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Drugs for Oncology Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Drugs for Oncology Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Drugs for Oncology Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Drugs for Oncology Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Drugs for Oncology Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Drugs for Oncology Market Size by Country (2022-2027) & (US$ Million)
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Drugs for Oncology Product
Table 67. Roche Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 68. Roche Recent Development
Table 69. Celgene Company Details
Table 70. Celgene Business Overview
Table 71. Celgene Drugs for Oncology Product
Table 72. Celgene Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 73. Celgene Recent Development
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Drugs for Oncology Product
Table 77. Novartis Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 78. Novartis Recent Development
Table 79. Bristol-Myers Squibb Company Details
Table 80. Bristol-Myers Squibb Business Overview
Table 81. Bristol-Myers Squibb Drugs for Oncology Product
Table 82. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 83. Bristol-Myers Squibb Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Drugs for Oncology Product
Table 87. Johnson & Johnson Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Merck & Co. Company Details
Table 90. Merck & Co. Business Overview
Table 91. Merck & Co. Drugs for Oncology Product
Table 92. Merck & Co. Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 93. Merck & Co. Recent Development
Table 94. AstraZeneca Company Details
Table 95. AstraZeneca Business Overview
Table 96. AstraZeneca Drugs for Oncology Product
Table 97. AstraZeneca Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 98. AstraZeneca Recent Development
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 102. Pfizer Recent Development
Table 103. Amgen Company Details
Table 104. Amgen Business Overview
Table 105. Amgen Drugs for Oncology Product
Table 106. Amgen Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 107. Amgen Recent Development
Table 108. Eli Lilly Company Details
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Drugs for Oncology Product
Table 111. Eli Lilly Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 112. Eli Lilly Recent Development
Table 113. AbbVie Company Details
Table 114. AbbVie Business Overview
Table 115. AbbVie Drugs for Oncology Product
Table 116. AbbVie Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 117. AbbVie Recent Development
Table 118. Takeda Company Details
Table 119. Takeda Business Overview
Table 120. Takeda Drugs for Oncology Product
Table 121. Takeda Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 122. Takeda Recent Development
Table 123. Astellas Company Details
Table 124. Astellas Business Overview
Table 125. Astellas Drugs for Oncology Product
Table 126. Astellas Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 127. Astellas Recent Development
Table 128. Ipsen Company Details
Table 129. Ipsen Business Overview
Table 130. Ipsen Drugs for Oncology Product
Table 131. Ipsen Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 132. Ipsen Recent Development
Table 133. Sanofi Company Details
Table 134. Sanofi Business Overview
Table 135. Sanofi Drugs for Oncology Product
Table 136. Sanofi Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 137. Sanofi Recent Development
Table 138. Bayer Company Details
Table 139. Bayer Business Overview
Table 140. Bayer Drugs for Oncology Product
Table 141. Bayer Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 142. Bayer Recent Development
Table 143. Biogen Idec Company Details
Table 144. Biogen Idec Business Overview
Table 145. Biogen Idec Drugs for Oncology Product
Table 146. Biogen Idec Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 147. Biogen Idec Recent Development
Table 148. Teva Company Details
Table 149. Teva Business Overview
Table 150. Teva Drugs for Oncology Product
Table 151. Teva Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 152. Teva Recent Development
Table 153. Otsuka Company Details
Table 154. Otsuka Business Overview
Table 155. Otsuka Drugs for Oncology Product
Table 156. Otsuka Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 157. Otsuka Recent Development
Table 158. Eisai Company Details
Table 159. Eisai Business Overview
Table 160. Eisai Drugs for Oncology Product
Table 161. Eisai Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 162. Eisai Recent Development
Table 163. Merck KGaA Company Details
Table 164. Merck KGaA Business Overview
Table 165. Merck KGaA Drugs for Oncology Product
Table 166. Merck KGaA Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 167. Merck KGaA Recent Development
Table 168. Gilead Sciences Company Details
Table 169. Gilead Sciences Business Overview
Table 170. Gilead Sciences Drugs for Oncology Product
Table 171. Gilead Sciences Revenue in Drugs for Oncology Business (2016-2021) & (US$ Million)
Table 172. Gilead Sciences Recent Development
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Oncology Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Immunotherapy (Biologic Therapy) Features
Figure 5. Hormonal Therapy Features
Figure 6. Others Features
Figure 7. Global Drugs for Oncology Market Share by Application: 2020 VS 2027
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Respiratory/Lung Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Drugs for Oncology Report Years Considered
Figure 15. Global Drugs for Oncology Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Drugs for Oncology Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Drugs for Oncology Market Share by Regions: 2020 VS 2027
Figure 18. Global Drugs for Oncology Market Share by Regions (2022-2027)
Figure 19. Global Drugs for Oncology Market Share by Players in 2020
Figure 20. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2020
Figure 22. Global Drugs for Oncology Revenue Market Share by Type (2016-2021)
Figure 23. Global Drugs for Oncology Revenue Market Share by Type (2022-2027)
Figure 24. North America Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Drugs for Oncology Market Share by Type (2016-2027)
Figure 26. North America Drugs for Oncology Market Share by Application (2016-2027)
Figure 27. North America Drugs for Oncology Market Share by Country (2016-2027)
Figure 28. United States Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Drugs for Oncology Market Share by Type (2016-2027)
Figure 32. Europe Drugs for Oncology Market Share by Application (2016-2027)
Figure 33. Europe Drugs for Oncology Market Share by Country (2016-2027)
Figure 34. Germany Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Drugs for Oncology Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Drugs for Oncology Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Drugs for Oncology Market Share by Region (2016-2027)
Figure 44. China Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Drugs for Oncology Market Share by Type (2016-2027)
Figure 52. Latin America Drugs for Oncology Market Share by Application (2016-2027)
Figure 53. Latin America Drugs for Oncology Market Share by Country (2016-2027)
Figure 54. Mexico Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Drugs for Oncology Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Drugs for Oncology Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Drugs for Oncology Market Share by Country (2016-2027)
Figure 60. Turkey Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Drugs for Oncology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Roche Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 64. Celgene Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 67. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 68. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 69. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 70. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 71. Amgen Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 72. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 73. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 74. Takeda Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 75. Astellas Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 76. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 77. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 78. Bayer Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 79. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 80. Teva Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 81. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 82. Eisai Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 83. Merck KGaA Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 84. Gilead Sciences Revenue Growth Rate in Drugs for Oncology Business (2016-2021)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

---